세포 및 유전자 치료용 제조 서비스 시장, 기회, 성장 동력, 산업 동향 분석 및 예측(2024-2032년)

The Global Cell & Gene Therapy Manufacturing Services Market, worth USD 5.9 billion in 2023, will expand to an 18.9% CAGR from 2024 to 2032, driven by advancements in cell and gene therapies and the growing number of clinical trials. Innovations in gene editing and cell-based treatments are expanding therapeutic possibilities, increasing demand for specialized manufacturing. Additionally, the rise in clinical trials for new therapies amplifies the need for scalable and compliant manufacturing solutions. This combination of technological progress and active clinical research will boost market growth and drive the demand for advanced manufacturing services.

The overall cell & gene therapy manufacturing services industry is segregated based on type, indication, mode, end use r, and region.

The cell therapy segment captured a 60.6% share in 2023 and will grow at an 18.6% CAGR through 2032, spurred by its widespread application and ongoing advancements. As cell therapies, including CAR-T and stem cell treatments, gain traction in treating various conditions, the demand for specialized manufacturing services increases. The complexity and customization required for cell therapies drive the need for sophisticated manufacturing processes. With continuous innovation and a growing number of clinical applications, the cell therapy segment will lead the market.

The contract manufacturing segment will reach USD 21.3 billion by 2032, attributed to its cost-effectiveness and expertise. Contract manufacturing organizations (CMOs) offer specialized services that address the complex and scalable needs of cell and gene therapies, from production to quality control. Their ability to provide advanced technologies and regulatory compliance, along with the flexibility to scale operations, makes them essential partners for therapy developers. As demand for these therapies grows, the contract manufacturing segment will dominate the market.

North America will register an 18.1% CAGR through 2032 due to its advanced healthcare infrastructure, significant investments in biotechnology, and a high concentration of leading pharmaceutical and biotech companies. The region's robust regulatory environment and strong research and development capabilities further bolster its position. As the demand for cutting-edge therapies grows, North America's established expertise and resources make it a crucial contributor to the global cell & gene therapy manufacturing services market.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of cancer and other diseases
    • 3.2.1.2 Increasing government grants and support for development of cell and gene therapies
    • 3.2.1.3 Increasing pharmaceutical R and D spending
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High risk of mutagenesis
    • 3.2.2.2 Lack of standardized production systems for cell and gene therapy products
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 U.S.
  • 3.4.2 Canada
  • 3.4.3 Europe
• 3.5 Technology landscape
• 3.6 Pipeline analysis
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
  • 4.1.1 Thermo Fisher Scientific Inc.
  • 4.1.2 Boehringer Ingelheim International GmbH
  • 4.1.3 Merck KGaA
• 4.2 Company market share analysis
• 4.3 Competitive analysis of major market players
• 4.4 Company matrix analysis
• 4.5 Vendor matrix analysis
• 4.6 Competitive positioning matrix
• 4.7 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Cell therapy
  • 5.2.1 Allogenic
    • 5.2.1.1 Mesenchymal stem cells
    • 5.2.1.2 T-cells
    • 5.2.1.3 Natural killer cells
    • 5.2.1.4 Hematopoietic stem cells
    • 5.2.1.5 Other allogeneic cells
  • 5.2.2 Autologous
    • 5.2.2.1 Mesenchymal stem cells
    • 5.2.2.2 T-cells
    • 5.2.2.3 Natural killer cells
    • 5.2.2.4 Hematopoietic stem cells
    • 5.2.2.5 Other allogeneic cells
• 5.3 Gene therapy
  • 5.3.1 Viral vectors
  • 5.3.2 Non-viral vectors

Chapter 6 Market Estimates and Forecast, By Mode, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Contract manufacturing
• 6.3 In-house manufacturing

Chapter 7 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oncology diseases
• 7.3 Cardiovascular diseases
• 7.4 Orthopedic diseases
• 7.5 Infectious diseases
• 7.6 Ophthalmology diseases
• 7.7 Other indications

Chapter 8 Market Estimates and Forecast, By End user, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Biopharmaceutical companies
• 8.3 Academic research institutes
• 8.4 Hospitals

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Boehringer Ingelheim International GmbH
• 10.2 Bluebird Bio, Inc.
• 10.3 Catalent, Inc.
• 10.4 Charles River Laboratories International, Inc.
• 10.5 Merck KGaA
• 10.6 Miltenyi Bioindustry (Miltenyi Biotec)
• 10.7 Samsung Biologics
• 10.8 Takara Bio Inc.
• 10.9 Thermo Fisher Scientific Inc
• 10.10 WuXi AppTec Co., Ltd.